Levetiracetam Eignapharma (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release and stabilizes neuronal excitability, thereby reducing the likelihood of seizure propagation.

The dosage of levetiracetam is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and clinical response. Specific dosing regimens are not provided here.

Safety data for levetiracetam in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Levetiracetam has a distinct mechanism (SV2A binding) and a relatively favorable interaction profile compared with many enzyme‑inducing antiepileptics. It is often chosen for its rapid intravenous onset and minimal hepatic metabolism, though individual response and tolerability vary.

Levetiracetam Eignapharma should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

The product is supplied as an injectable solution for intravenous administration. It is typically infused over a short period under medical supervision, following the dosing instructions provided by the treating physician.

Serious risks include severe allergic reactions such as anaphylaxis, life‑threatening skin conditions like Stevens‑Johnson syndrome, suicidal thoughts or behaviors, and rare blood disorders. Patients should be monitored for any signs of these reactions.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for patients with severe renal impairment where dose adjustment may not be feasible.